Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.

ABSTRACT:

Purpose

Several Src family kinase (SFK) inhibitors have entered clinical trials based on their direct effects against tumor cells. Here, we characterize the effects of targeting Src kinases on the tumor microenvironment and how these effects influence tumor growth.

Experimental design

Human cancer cells grown in cell culture or in mice were treated with dasatinib, a small-molecule inhibitor of SFKs. Tumor cell, endothelial cell, and myeloid cell compartments within the tumor microenvironment were analyzed. Primary human endothelial cells and freshly isolated CD11b+/CD11c- myeloid cells from mice were treated with dasatinib in cell culture. Cellular functions and signaling pathways affected by dasatinib were evaluated.

Results

Dasatinib was not cytotoxic in cell cultur

SUBMITTER: Liang W 

PROVIDER: S-EPMC2818562 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature